ES2732276T3 - Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo - Google Patents
Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo Download PDFInfo
- Publication number
- ES2732276T3 ES2732276T3 ES11158929T ES11158929T ES2732276T3 ES 2732276 T3 ES2732276 T3 ES 2732276T3 ES 11158929 T ES11158929 T ES 11158929T ES 11158929 T ES11158929 T ES 11158929T ES 2732276 T3 ES2732276 T3 ES 2732276T3
- Authority
- ES
- Spain
- Prior art keywords
- tsh receptor
- amino acids
- tsh
- autoantibodies
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000015486 thyroid-stimulating hormone receptor activity proteins Human genes 0.000 title description 4
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 title description 4
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims abstract description 833
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims abstract description 833
- 239000012634 fragment Substances 0.000 claims abstract description 252
- 230000027455 binding Effects 0.000 claims abstract description 94
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 63
- 239000002157 polynucleotide Substances 0.000 claims abstract description 63
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 63
- 108010032595 Antibody Binding Sites Proteins 0.000 claims abstract description 15
- 210000001685 thyroid gland Anatomy 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000000638 stimulation Effects 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 108010066702 Thyrotropin Alfa Proteins 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 description 452
- 150000001413 amino acids Chemical class 0.000 description 449
- 108090000765 processed proteins & peptides Proteins 0.000 description 264
- 102000004196 processed proteins & peptides Human genes 0.000 description 262
- 229920001184 polypeptide Polymers 0.000 description 255
- 210000004698 lymphocyte Anatomy 0.000 description 192
- 230000003993 interaction Effects 0.000 description 155
- 125000003275 alpha amino acid group Chemical group 0.000 description 133
- 230000004044 response Effects 0.000 description 131
- 239000003446 ligand Substances 0.000 description 77
- 239000002773 nucleotide Substances 0.000 description 73
- 125000003729 nucleotide group Chemical group 0.000 description 73
- 238000000034 method Methods 0.000 description 66
- 102000005962 receptors Human genes 0.000 description 55
- 108020003175 receptors Proteins 0.000 description 55
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 54
- 210000001124 body fluid Anatomy 0.000 description 54
- 239000010839 body fluid Substances 0.000 description 54
- 102100029337 Thyrotropin receptor Human genes 0.000 description 47
- 208000023275 Autoimmune disease Diseases 0.000 description 45
- 230000008105 immune reaction Effects 0.000 description 39
- 241000282414 Homo sapiens Species 0.000 description 27
- 238000003745 diagnosis Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000012544 monitoring process Methods 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 241001494479 Pecora Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 241000283690 Bos taurus Species 0.000 description 13
- 208000015023 Graves' disease Diseases 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 208000023328 Basedow disease Diseases 0.000 description 12
- 241000282465 Canis Species 0.000 description 12
- 241000282324 Felis Species 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000002372 labelling Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108010061174 Thyrotropin Proteins 0.000 description 9
- 102000011923 Thyrotropin Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000012875 competitive assay Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 8
- 229940095074 cyclic amp Drugs 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229950001470 thyrotrophin Drugs 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000002860 competitive effect Effects 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 239000005495 thyroid hormone Substances 0.000 description 6
- 229940036555 thyroid hormone Drugs 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940045662 porcine thyroid Drugs 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 102000051345 human TSHR Human genes 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000010807 negative regulation of binding Effects 0.000 description 4
- 230000036963 noncompetitive effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010036012 Iodide peroxidase Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 102000014267 Thyroid peroxidases Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000000599 auto-anti-genic effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101500025562 Homo sapiens Saposin-A Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 1
- 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- -1 aliphatic amino acids Chemical class 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0120649A GB0120649D0 (en) | 2001-08-23 | 2001-08-23 | Epitope regions of a thyrotrophin (TSH) receptor and uses thereof |
| GB0215212A GB0215212D0 (en) | 2002-07-01 | 2002-07-01 | Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2732276T3 true ES2732276T3 (es) | 2019-11-21 |
Family
ID=26246470
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11158929T Expired - Lifetime ES2732276T3 (es) | 2001-08-23 | 2002-08-21 | Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo |
| ES02755210.8T Expired - Lifetime ES2466377T3 (es) | 2001-08-23 | 2002-08-21 | Regiones epitópicas de un receptor de tirotropina (TSH), usos de las mismas y anticuerpos para las mismas |
| ES11158927T Expired - Lifetime ES2736165T3 (es) | 2001-08-23 | 2002-08-21 | Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02755210.8T Expired - Lifetime ES2466377T3 (es) | 2001-08-23 | 2002-08-21 | Regiones epitópicas de un receptor de tirotropina (TSH), usos de las mismas y anticuerpos para las mismas |
| ES11158927T Expired - Lifetime ES2736165T3 (es) | 2001-08-23 | 2002-08-21 | Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8298769B2 (OSRAM) |
| EP (3) | EP1456234B1 (OSRAM) |
| JP (2) | JP2005509412A (OSRAM) |
| CN (3) | CN101799476B (OSRAM) |
| ES (3) | ES2732276T3 (OSRAM) |
| WO (1) | WO2003018632A2 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101799476B (zh) | 2001-08-23 | 2013-01-02 | Rsr有限公司 | 筛选针对tsh受体的自身抗体的试剂盒 |
| JP5314234B2 (ja) * | 2002-11-29 | 2013-10-16 | アールエスアール リミテッド | チロトロピン受容体の結合対象及びその使用 |
| EP1612224B1 (en) | 2004-06-29 | 2012-03-07 | B.R.A.H.M.S GmbH | Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine |
| GB0418181D0 (en) | 2004-08-13 | 2004-09-15 | Rsr Ltd | Thyrotrophin receptor preparations,thyrotrophin receptor epitopes,antibody and hormone interactions therewith,and uses thereof |
| WO2007057778A2 (en) * | 2005-11-21 | 2007-05-24 | Dr. Fenning Biomed Gmbh | Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor |
| JP5165672B2 (ja) * | 2006-03-29 | 2013-03-21 | キングス カレッジ ロンドン | Ｔｓｈｒに対するアゴニスト抗体 |
| ES2550158T3 (es) * | 2007-08-06 | 2015-11-04 | Chugai Seiyaku Kabushiki Kaisha | Método para medir la actividad inhibidora sobre la unión ligando-receptor |
| EP2617735A3 (en) * | 2008-12-24 | 2013-10-16 | Rsr Limited | Human anti tshr antibodies |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| KR102585625B1 (ko) * | 2014-12-24 | 2023-10-05 | 아피토프 인터내셔날 엔브이 | 조성물 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| AU2018355427A1 (en) | 2017-10-25 | 2020-04-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US12441815B2 (en) | 2018-11-02 | 2025-10-14 | The Regents Of The University Of California | Compositions and methods for diagnosis of cardiovascular disease |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| KR20220116522A (ko) | 2019-12-20 | 2022-08-23 | 노파르티스 아게 | 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| KR20250057832A (ko) * | 2022-08-31 | 2025-04-29 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도 |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244940A (en) | 1978-09-05 | 1981-01-13 | Bio-Rad Laboratories, Inc. | Single-incubation two-site immunoassay |
| US4514498A (en) | 1982-05-26 | 1985-04-30 | The Board Of Regents, The University Of Texas System | Hybrid cell lines producing monoclonal antibodies directed against Treponema |
| US4472508A (en) | 1982-12-30 | 1984-09-18 | The Beth Israel Hospital Association | Test for detecting and measuring the graves' disease-specific immunoglobulins |
| WO1984003106A1 (en) | 1983-02-04 | 1984-08-16 | Wadley Inst Of Molecular Medic | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| US4609622A (en) | 1983-05-31 | 1986-09-02 | Interthyr Research Foundation Inc. | Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5 |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4661446A (en) | 1985-02-19 | 1987-04-28 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies and method of immunizing therewith |
| WO1990008528A1 (en) | 1989-01-11 | 1990-08-09 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Biologically active synthetic thyrotropin and cloned gene for producing same |
| DK0614975T3 (da) | 1989-05-05 | 2002-11-11 | Genentech Inc | Glycoproteinhormonreceptormolekyler |
| US6261800B1 (en) | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
| US5614363A (en) | 1990-01-25 | 1997-03-25 | New England Medical Center Hospitals, Inc. | TSH receptor |
| US5744348A (en) | 1989-09-08 | 1998-04-28 | New England Medical Center Hospitals, Inc. | TSH receptor |
| DE68927461T2 (de) * | 1989-12-14 | 1997-03-20 | B.R.A.H.M.S Diagnostica Gmbh, 12099 Berlin | Polypeptide mit Thyrotropinrezeptor-Aktivität, kodierende Nukleinsäuresequenzen für solche Rezeptoren und Verwendung dieser Polypeptide |
| WO1991009137A1 (en) | 1989-12-20 | 1991-06-27 | Basil Rapoport | Recombinant thyrotropin receptor |
| JPH04149197A (ja) * | 1990-10-12 | 1992-05-22 | Tanabe Seiyaku Co Ltd | 新規ペプチド |
| EP0482598A3 (en) | 1990-10-24 | 1993-05-19 | Ishihara Sangyo Kaisha, Ltd. | Peptide analog of human tsh receptor affective against autoimmune hyperthyroidism |
| US5578496A (en) | 1991-12-19 | 1996-11-26 | Board Of Regents, Baylor College Of Medicine | Detection of autoantibodies associated with the disease myasthenia gravis |
| AU679439B2 (en) | 1992-02-10 | 1997-07-03 | Duke University | Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens |
| US5705400A (en) | 1992-03-07 | 1998-01-06 | Rsr Limited | Assay for adrenal autoantigen |
| US5195860A (en) | 1992-07-20 | 1993-03-23 | Trw Inc. | Push-on type fastener for automatic feed and installation equipment |
| JPH06220089A (ja) * | 1993-01-27 | 1994-08-09 | Ishihara Sangyo Kaisha Ltd | ペプチド又はその塩並びにそれらを含有する自己免疫性甲状腺疾患の診断薬又は治療薬 |
| WO1994018566A1 (fr) | 1993-02-04 | 1994-08-18 | Sumitomo Pharmaceuticals Company, Limited | Procede de dosage d'un anticorps specifique |
| DE4328070C1 (de) | 1993-08-20 | 1994-11-24 | Henning Berlin Gmbh | Verfahren zur Bestimmung eines Analyten in einem Volumen einer flüssigen Probe sowie seine Anwendung zur Bestimmung von anti-TSH-Rezeptor-Autoantikörpern in einem Patientenserum |
| JPH0789991A (ja) * | 1993-09-28 | 1995-04-04 | Mitsubishi Chem Corp | 新規なポリペプチドおよびそれを用いるｔｓｈ受容体抗体の測定法 |
| EP0719858A3 (en) | 1994-12-27 | 1997-12-29 | Tosoh Corporation | Myeloma cell line expressing recombinant human thyroid stimulating hormone receptor |
| DE19505266C1 (de) | 1995-02-16 | 1996-10-02 | Brahms Diagnostica Gmbh | Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren |
| DE19522171C1 (de) | 1995-06-19 | 1996-08-22 | Brahms Diagnostica Gmbh | Verfahren zur Bestimmung von Anti-TSH-Rezeptor-Autoantikörpern |
| US5723343A (en) | 1995-08-28 | 1998-03-03 | University Of Florida | Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor |
| DE19728991A1 (de) | 1996-11-06 | 1999-02-11 | Brahms Diagnostica Gmbh | Rezeptorbindungsassay, für den Rezeptorbindungsassay geeigneter rekombinanter Fusionsrezeptor, Vektor zu dessen Herstellung sowie Reagenziensatz für die Durchführung des Rezeptorbindungsassays |
| US5734464A (en) | 1996-11-06 | 1998-03-31 | Cobe Laboratories, Inc. | Red blood cell spillover detection technique |
| US6692625B1 (en) | 1996-11-06 | 2004-02-17 | Robert Bosch Gmbh | Electrochemical sensor |
| DE19651093C2 (de) * | 1996-12-09 | 1999-06-10 | Brahms Diagnostica Gmbh | Rezeptorbindungsassay zum Nachweis von TSH-Rezeptor-Autoantikörpern sowie Reagenziensatz für die Durchführung eines solchen Rezeptorbindungsassays |
| IL123888A0 (en) | 1997-04-01 | 1998-10-30 | Sankyo Co | Anti-fas antibodies |
| GB9909661D0 (en) * | 1998-06-06 | 1999-06-23 | Rsr Ltd | Assays for TSH receptor autoantibodies |
| WO2000005345A1 (en) * | 1998-07-21 | 2000-02-03 | Basil Rapoport | Human thyrotropin receptor compositions and use thereof |
| GB9823397D0 (en) * | 1998-10-27 | 1998-12-23 | Rsr Ltd | Assays for thyroid autoantibodies |
| JP4427878B2 (ja) * | 1999-08-20 | 2010-03-10 | 味の素株式会社 | 析出を伴う発酵法によるｌ−グルタミン酸の製造法 |
| EP1078986B1 (en) * | 1999-08-24 | 2007-02-28 | Tosoh Corporation | Secretory thyroid stimulating hormone receptor (TSHR), and method for assaying anti-TSHR antibody using the same |
| ES2248133T3 (es) | 1999-10-12 | 2006-03-16 | Ulrich Loos | Procedimiento para la determinacion de autoanticuerpos contra el receptor de tsh. |
| WO2001044300A2 (en) | 1999-12-13 | 2001-06-21 | Cambridge Antibody Technology Limited | Brain specific binding members |
| DE50106201D1 (de) | 2000-02-21 | 2005-06-16 | Brahms Ag | Verfahren zur differentialdiagnostischen bestimmung von gegen den tsh-rezeptor gebildeten autoantikörpern in einer serum- oder plasmaprobe eines patienten |
| JP5198704B2 (ja) | 2000-03-03 | 2013-05-15 | メディミューン リミティド | エオタキシンに対するヒト抗体及びそれらの使用 |
| US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| DE10126968A1 (de) | 2001-06-01 | 2002-12-12 | Ivoclar Vivadent Ag | Farbstoffzusammensetzung zum individuellen Einfärben von Prothesenkunststoffen |
| CN101799476B (zh) | 2001-08-23 | 2013-01-02 | Rsr有限公司 | 筛选针对tsh受体的自身抗体的试剂盒 |
| JP5314234B2 (ja) | 2002-11-29 | 2013-10-16 | アールエスアール リミテッド | チロトロピン受容体の結合対象及びその使用 |
| US8840891B2 (en) * | 2007-02-15 | 2014-09-23 | Rsr Limited | Human monoclonal antibodies to the thyrotropin receptor which act as antagonists |
| EP2617735A3 (en) * | 2008-12-24 | 2013-10-16 | Rsr Limited | Human anti tshr antibodies |
-
2002
- 2002-08-21 CN CN2010101273436A patent/CN101799476B/zh not_active Expired - Lifetime
- 2002-08-21 US US10/488,074 patent/US8298769B2/en not_active Expired - Fee Related
- 2002-08-21 EP EP02755210.8A patent/EP1456234B1/en not_active Expired - Lifetime
- 2002-08-21 WO PCT/GB2002/003831 patent/WO2003018632A2/en not_active Ceased
- 2002-08-21 CN CN201310075812.8A patent/CN103224562B/zh not_active Expired - Lifetime
- 2002-08-21 ES ES11158929T patent/ES2732276T3/es not_active Expired - Lifetime
- 2002-08-21 EP EP11158929.7A patent/EP2383291B1/en not_active Expired - Lifetime
- 2002-08-21 JP JP2003523491A patent/JP2005509412A/ja active Pending
- 2002-08-21 ES ES02755210.8T patent/ES2466377T3/es not_active Expired - Lifetime
- 2002-08-21 EP EP11158927.1A patent/EP2383290B1/en not_active Expired - Lifetime
- 2002-08-21 ES ES11158927T patent/ES2736165T3/es not_active Expired - Lifetime
- 2002-08-21 CN CN028164229A patent/CN1622958B/zh not_active Expired - Lifetime
-
2008
- 2008-12-12 US US12/333,714 patent/US8309693B2/en not_active Expired - Fee Related
- 2008-12-12 US US12/333,740 patent/US8298771B2/en not_active Expired - Fee Related
-
2009
- 2009-07-22 JP JP2009171358A patent/JP5576072B2/ja not_active Expired - Lifetime
-
2012
- 2012-11-09 US US13/673,878 patent/US9751940B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8298771B2 (en) | 2012-10-30 |
| US8298769B2 (en) | 2012-10-30 |
| EP2383290B1 (en) | 2019-05-08 |
| US9751940B2 (en) | 2017-09-05 |
| WO2003018632A2 (en) | 2003-03-06 |
| EP1456234A2 (en) | 2004-09-15 |
| US20090202438A1 (en) | 2009-08-13 |
| ES2736165T3 (es) | 2019-12-26 |
| JP2005509412A (ja) | 2005-04-14 |
| US20090203036A1 (en) | 2009-08-13 |
| US20130089561A1 (en) | 2013-04-11 |
| CN101799476B (zh) | 2013-01-02 |
| WO2003018632A3 (en) | 2004-06-17 |
| EP2383291A2 (en) | 2011-11-02 |
| EP2383290A2 (en) | 2011-11-02 |
| EP1456234B1 (en) | 2014-04-09 |
| CN103224562A (zh) | 2013-07-31 |
| CN103224562B (zh) | 2017-09-08 |
| ES2466377T3 (es) | 2014-06-10 |
| JP5576072B2 (ja) | 2014-08-20 |
| CN1622958B (zh) | 2013-04-03 |
| EP2383290A3 (en) | 2012-10-10 |
| EP2383291B1 (en) | 2019-04-17 |
| CN1622958A (zh) | 2005-06-01 |
| CN101799476A (zh) | 2010-08-11 |
| US8309693B2 (en) | 2012-11-13 |
| EP2383291A3 (en) | 2013-02-13 |
| US20050118638A1 (en) | 2005-06-02 |
| JP2009278998A (ja) | 2009-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2732276T3 (es) | Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo | |
| JP2009278998A5 (OSRAM) | ||
| ES2225820T3 (es) | Receptor cd40cr y ligandos del mismo. | |
| EP0701569B1 (en) | Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome | |
| WO1994012529A9 (en) | Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome | |
| KR20220122467A (ko) | 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도 | |
| JPH02479A (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| Abréu Vélez et al. | The tryptic cleavage product of the mature form of the bovine desmoglein I ectodomain is one of the antigen moieties immunoprecipitated by all sera from symptomatic patients affected by a new variant of endemic pemphigus | |
| Hayakawa et al. | Isolation and characterization of human monoclonal autoantibodies to glutamic acid decarboxylase | |
| Harcourt et al. | Detection of α-subunit isoforms in human muscle acetylcholine receptor by specific T cells from a myasthenia gravis patient | |
| Gomez et al. | Changes in the specificity of antibodies in mice infected with lactate dehydrogenase‐elevating virus | |
| EP1360280B1 (en) | Tissue transglutaminase | |
| Kosugi et al. | Epitope analysis of the thyrotropin receptor, 1997 | |
| MATSUI et al. | Biological activities of rat antisera raised against synthetic peptides of human thyrotropin receptor | |
| CN118359717A (zh) | 抗nmda受体自身免疫性脑炎新型抗体及其用途 | |
| EA004228B1 (ru) | МОДУЛЯТОР ИММУННОГО ОТВЕТА α- МАКРОГЛОБУЛИНОВЫЙ КОМПЛЕКС | |
| Manns | Autoantibodies to cytochrome P450s in idiopathic autoimmune type chronic active hepatitis |